SCHEMBL30633765

SCHEMBL30633765

Cc1cn(C(C)C)c2cc(Br)ccc2c1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.38
NLRP3 Q96P20 2/20 0.35
LMNA P02545 3/20 0.34
HPGD P15428 2/20 0.34
PDGFRA P16234 1/20 0.33
CDK5 Q00535 1/20 0.33
TYRO3 Q06418 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HTT P42858 1/20 0.33
NR3C1 P04150 1/20 0.33
PGR P06401 1/20 0.33
NR3C2 P08235 1/20 0.33
AR P10275 1/20 0.33
MGAM O43451 1/20 0.33
GAA P10253 1/20 0.33
SI P14410 1/20 0.33
MGAM2 Q2M2H8 1/20 0.33
MAPK8 P45983 1/20 0.32
CHEK1 O14757 1/20 0.32
CA1 P00915 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26613868 1.00 PDE4B (0.38) PDE4BNLRP3LMNAHPGDPDGFRA
SCHEMBL16727194 0.87 PDE4B (0.41) PDE4BLMNAHPGDPDGFRACDK5
SCHEMBL30633681 0.83 LMNA (0.40) PDE4BNLRP3LMNAPDGFRACDK5
SCHEMBL26613849 0.83 LMNA (0.40) PDE4BNLRP3LMNAPDGFRACDK5
SCHEMBL23497546 0.81 PTPN1 (0.41) PDE4BNLRP3LMNAPDGFRACDK5
SCHEMBL30633790 0.81 RXFP1 (0.36) PDE4BNLRP3LMNAALDH1A1NR3C1
SCHEMBL29744434 0.81 PTPN1 (0.41) PDE4BNLRP3LMNAPDGFRACDK5
SCHEMBL26613864 0.81 RXFP1 (0.36) PDE4BNLRP3LMNAALDH1A1NR3C1
SCHEMBL30633673 0.80 NLRP3 (0.40) PDE4BNLRP3LMNAPDGFRACDK5
SCHEMBL23497662 0.80 MYC (0.38) NLRP3LMNAHPGDALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136586-A1 Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors BEIGENE, LTD. (KY) 2025-05-01 US disclosed
EP-4514797-A1 SUBSTITUTED 7- (PYRIMIDIN-4-YL) QUINOLIN-4 (1H) -ONE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS BeiGene, Ltd. (KY) 2025-03-05 EP disclosed
CN-119053598-A Substituted 7- (pyrimidin-4-yl) quinolin-4 (1H) -one compounds as cyclin dependent kinase inhibitors 百济神州有限公司 2024-11-29 CN disclosed
WO-2023208172-A1 SUBSTITUTED 7- (PYRIMIDIN-4-YL) QUINOLIN-4 (1H) -ONE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS BEIGENE , LTD. (KY) 2023-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136586-A1 Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors CDK4, CDK7, CDK8 PDE4B 1164/4885NLRP3 3820/4885LMNA 2216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.